Bristol-Myers says cancer drug combo reduces death risk
Bristol-Myers Squibb said on Monday its cancer drugs, Opdivo and Yervoy, reduced the risk of the disease spreading or death in previously untreated patients with a type of lung cancer.
The combination demonstrated a higher rate of progression-free survival, compared with chemotherapy in a late-stage trial, the company said.
The results come a week after rival Merck & Co said a trial testing its blockbuster drug Keytruda as a monotherapy in previously untreated lung cancer patients was successful.
(Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)
Bristol-MyersBristol-Myers Squibbcancer drug combochemotherapydeathdeath riskKeytrudalung cancerMerckOpdivoreducesYervoy
Source : REUTERSNext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd